News . Data . Research
CERo Therapeutics Holdings, Inc. is a biotechnology company pioneering engineered T cell immunotherapies to combat cancer, with a focus on hematologic malignancies
Pharmaceuticals company Viatris Inc. (NASDAQ: VTRS) on Thursday reported financial results for the third quarter of fiscal 2025, and updated its outlook
Humana Inc. (NYSE: HUM), a leading health and well-being company, on Wednesday reported a decline in adjusted earnings for the third quarter
Shares of Pfizer Inc. (NYSE: PFE) stayed green during midday trade on Tuesday following the company’s announcement of its third quarter 2025
Pfizer Inc. (NYSE: PFE) reported its third quarter 2025 earnings results today. Revenues were $16.7 billion, down 6% on a reported basis
Pharmaceuticals company AbbVie, Inc. (NYSE: ABBV) on Friday reported a decline in earnings for the third quarter of fiscal 2025, despite an
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported an increase in adjusted profit for the third quarter of 2025 when its revenues remained
Pharmaceuticals distributor Cardinal Health (NYSE: CAH) reported a sharp increase in revenue and adjusted earnings for the first quarter of fiscal 2026.
Bristol Myers Squibb (NYSE: BMY) reported its third quarter 2025 earnings results today. Revenues increased 3% year-over-year to $12.2 billion. GAAP net
Eli Lilly and Company (NYSE: LLY) reported its third quarter 2025 earnings results today. Worldwide revenue was $17.60 billion, up 54% from
Merck & Co., Inc. (NYSE: MRK) reported its third quarter 2025 earnings results today. Total worldwide sales of $17.3 billion were up
Healthcare behemoth UnitedHealth Group (NYSE: UNH) announced results for the third quarter of fiscal 2025, reporting an increase in revenues and a
Abbott Laboratories (NYSE: ABT) reported higher sales and adjusted earnings for the third quarter of fiscal 2025. The healthcare company also reaffirmed
Kairos Pharma, Ltd. (NYSE: KAPA) is a biopharma company developing a pipeline of targeted therapies for cancer patients with high unmet medical
Johnson & Johnson (NYSE: JNJ) reported its third quarter 2025 earnings results today. Reported sales increased 6.8% year-over-year to $24 billion. Operational
In recent months, Wall Street has seen a surge of healthcare firms seeking to go public, as IPO activity continues to regain
For Johnson & Johnson (NYSE: JNJ), 2025 has been a strong year, marked by an impressive financial performance that drove the stock
McKesson Corporation (NYSE: MCK), a diversified healthcare service company that operates in partnership with biopharma companies and care providers, has published its
Cardinal Health (NYSE: CAH), a leading pharmaceuticals distributor, on Tuesday reported an increase in adjusted profit for the fourth quarter of 2025.
Eli Lilly and Company (NYSE: LLY) reported its second quarter 2025 earnings results today. Worldwide revenue was $15.56 billion, up 38% from
Eli Lilly and Company (NYSE: LLY) had a positive start to fiscal 2025, reporting strong revenue and earnings growth for the first